An interventional study of iCBT with human interaction and Psychoeducational videos in Depression Symptoms, Depression - Major Depressive Disorder and Depressive Disorder, sponsored by Francesc Colom, PsyD, PhD. Recruiting at 2 sites in Spain. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Francesc Colom, PsyD, PhD · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 225 studies in Depression with a site in Spain — 46 open to participants now, 58 under way, 7 of them phase 3. Depression · Spain.
Among the 225 studies in Depression with a site in Spain, this one is the 99th largest by planned enrollment of the 189 interventional ones that give a count, is one of 14 that started in 2026, is one of 153 with no phase, reaches primary completion later than 40 of the 57 other live ones, and was the 196th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →46 of the 225 studies in Depression with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, United States, Australia and 12 more countries
Ages 18–75
University of Seville · Sites in Spain
Ages 18+ · Women only · Healthy volunteers
University of Seville · Sites in Spain
Ages 18+ · Healthy volunteers
Fundació Sant Joan de Déu · Sites in Spain
Ages 18+
University of the Basque Country (UPV/EHU) · Sites in Spain
Ages 18–65
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
225 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 14 · Phase 3 18 · Phase 4 6
First in 2002; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 123 across the 189 interventional studies, 303 across the 36 observational. Of the 130 that completed or were terminated, 17 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 225 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Francesc Colom, PsyD, PhD as lead sponsor.
Francesc Colom, PsyD, PhD has 1 study filed under Depression — fewer than ten, so there is no comparison to draw.
9 of the studies in Depression with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
| NCT07925723Universidad Miguel Hernandez de ElcheALAS PROPIAS: Music Therapy for Women Experiencing Machista Violence in Intimate Partner Relationships | 2026-11-30 |
| NCT07292610University of Castilla-La ManchaImpact of Nut Consumption on Mental Health in Young Adults | 2026-12 |
| NCT05289258Universidad de CórdobaUnified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments | 2026-12-30 |
| NCT04084795Parc de Salut MarAugmentation of EMDR With tDCS in the Treatment of Fibromyalgia | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 225 studies in Depression with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the efficacy of a specially developed internet-based Cognitive Behavioural Therapy (CBT) programme with human interaction-referred to as the 3D programme-tailored specifically for women experiencing moderate depressive symptoms. We hypothesise that participation in the intervention will lead to greater improvements in depression severity, compared to receiving only brief psychoeducational videos, when used as an add-on to treatment as usual (TAU) in this population.
The 3D programme is a 10-week blended intervention that includes ten weekly online self-guided modules focused on depression and women's health, along with six individual video sessions with a health/clinical psychologist. The modules cover topics such as mood changes across the menstrual cycle, body image, stress, caregiving, and the impact of gender-based experiences on mental health.
To explore how biological factors may influence how participants respond to treatment, the study will collect biological samples. These will be analysed to track hormone and metabolic changes, with the goal of identifying biological markers that might predict who benefits most from the intervention.
Ultimately, the results of this study aim to improve access to effective and personalised mental health care for women by evaluating whether a structured and personalised online CBT programme can provide meaningful benefits.
OBJECTIVES Primary objective: To assess the impact of the 3D programme on depressive symptom severity compared to a psychoeducational control condition.
Secondary objectives: To evaluate improvements in overall functioning, quality of life, perceived stress, and menstruation-related distress. Additionally, the study will investigate metabolic signatures associated with treatment response, focusing on tryptophan and steroid hormone pathways.
HYPOTESES Main hypothesis: Participation in the 3D programme will lead to greater improvements in depression severity (measured by HDRS-17) compared to receiving only informational materials when used as an add-on to Treatment As Usual (TAU) in women experiencing moderate depressive episodes.
Secondary hypotheses:
SAMPLE SIZE ESTIMATION AND RECRUITMENT The optimal sample size is estimated to be 60 participants per group. This calculation is based on a Cohen's d effect size of 0.2, a 95% confidence interval, a statistical power of 90%, and an anticipated attrition rate of 20%. Sample size estimation was conducted using G* Power 3.1.7 software.
All patients meeting the inclusion and exclusion criteria will be invited to participate in the study by their treating team at the outpatient mental health facilities within Hospital del Mar. Additionally, gynaecologists at Hospital del Mar will be encouraged to refer patients suspected of experiencing depressive symptoms. In such cases, patients will be screened by the study psychologist/psychiatrist to confirm these symptoms. Recruitment will conclude upon reaching the target of 120 participants with complete data.
RANDOMISATION AND BLINDING Participants will be randomised in a 1:1 ratio using the REDCap randomisation module, which will automatically assign participants to either the experimental or control group through simple randomisation with equal allocation.
This study will implement single blinding. Due to the nature of the intervention, participants will be aware of their group assignment (experimental or control) following randomisation. Likewise, therapists delivering the intervention will be aware of the assigned group, as is standard practice in psychological intervention trials. To uphold the integrity of the blinding process, the following measures will be applied:
STUDY DESING Part 1. Randomised controlled trial The study follows a naturalistic treatment approach, ensuring that all participants continue their usual care. The study will be conducted in accordance with the CONSORT guidelines.
PART 2. Metabolic signature of treatment response The metabolic signature of treatment response will be characterised through the analysis of tryptophan and steroid-related pathways. All analyses will be conducted using methods developed and validated by the Applied Metabolomic Research Group at Hospital del Mar Research Institute, ensuring proper sample handling protocols as outlined in previous studies.
Tryptophan Metabolism:
Tryptophan pathway metabolites-including tryptophan, kynurenine, serotonin, 3-hydroxykynurenine, 5-hydroxyindoleacetic acid, and kynurenic acid-will be quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The analysis will follow the protocol established by Marcos et al.
Analysis will focus on the kynurenine/tryptophan (K/T) ratio, a marker of indoleamine-2,3-dioxygenase (IDO) activity, which plays a key role in immune regulation and inflammatory responses.
Additionally, serotonin synthesis and its relationship with tryptophan availability will be assessed, alongside the tryptophan/large neutral amino acid (LNAA) ratio, which serves as an indicator of tryptophan's availability for serotonin production. Data will be integrated using network analysis to identify potential associations between these metabolites and treatment response.
Steroid Hormones:
The steroid profile will be analysed to monitor key sex hormones (e.g., estradiol, testosterone, progesterone) and glucocorticoids (e.g., cortisol, 20α-DHE, and 20β-DHE), along with their metabolites. These hormones play a pivotal role in modulating inflammation and metabolic pathways, with altered levels linked to physiological stress responses and treatment outcomes. These measurements will be performed by LC-MS/MS, following the method previously outlined by the research group.
Biological Samples:
Analysis will be conducted using various biological matrices, including blood, saliva, urine, nails, and hair, to provide complementary insights. Saliva, blood, and urine samples will capture acute metabolic changes at the time of the visit, while nails and hair will reflect chronic metabolite production.
ASSESSMENTS Assessments will be carried out at baseline (T0), immediately following the intervention (3 months after baseline, T1), and at a follow-up assessment (6 months after baseline, T2).
The baseline assessment will include:
Clinical data and biological samples will be collected at all time points.
DATA MANAGEMENT All the data will be text-based (.docx) or numeric format (.xlsx). For all published files, a document record and change track will be included (author contact information, status, version, change reason and date, contents" description, title, origin of the data including a description of the measurement and/or experiment setup) in a separate metadata file for each characterization action called METADATA.ODS.
Data will be stored on a secure server at the Hospital del Mar Research Institute, in compliance with EU and Spanish data protection regulations (General Data Protection Regulation, GDPR, of May 25, 2018; and Organic Law 3/2018 of December 5, on the Protection of Personal Data and Guarantee of Digital Rights).
STATISTICAL ANALYSIS
Primary and Secondary Outcomes:
Analyses will follow an intention-to-treat (ITT) approach, including all participants according to their randomized allocation, regardless of adherence to the intervention.group. Linear mixed-effects models (LMMs) will be used to examine changes over time and between groups for the HDRS-17, WHO-DAS 2.0, EQ-5D-5L, PSS, and MEDI-Q scores. These models will include fixed effects for group, time, and their interaction, and a random intercept for participants to account for within-subject correlation over time. Where appropriate, subscale-level analyses and models using change scores will also be conducted for secondary outcomes. To further explore the temporal dynamics of the intervention's effects, post hoc simple effects analyses will be performed to probe significant interactions.
Additional Analyses:
LLMs and multiple linear regression models will be employed to identify predictors of clinical improvement. Additionally, moderator analyses using linear mixed models will assess whether levels of perceived stress (PSS), or menstrual distress (MEDI-Q) influence treatment response as measured by changes in HDRS-17 scores over time.
Exploratory Biomarker Analyses:
Partial Least Squares Regression (PLSR) and multiple regression will be conducted to model associations between metabolite profiles, their changes over time, and changes in depressive symptoms. Variable Importance in Projection (VIP) scores and cross-validation techniques will be applied to evaluate model performance and identify key predictive biomarkers. Additionally, metabolomic evolution will be assessed through exploratory factor analysis, grouping variables into latent factors.
The criteria were revised on the registry on Oct 9, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undertake the 3D programme, a 10-week internet-delivered cognitive behavioural therapy (iCBT) intervention tailored for women.
Behavioral: iCBT with human interaction
Participants will continue to receive their usual treatment for depression from their healthcare team throughout the study. Additionally, over 10 weeks, they will receive biweekly emails containing links to six brief educational video capsules covering depression causes, behavioural activation, hormonal cycle effects, sleep strategies, healthy habits, and relapse prevention.
Behavioral: Psychoeducational videos
The 3D programme is a 10-week online intervention based on Cognitive Behavioural Therapy (CBT), designed to support women's mental health. Participants will use the 3D website to complete 10 weekly self-guided modules that include videos, written materials, and interactive activities. Topics address depression and issues commonly experienced by women, such as hormonal changes, caregiving, body image, and sexism. All content is available in both video and text formats. Participants will also have six one-to-one video sessions with a trained health/clinical psychologist, who will tailor the programme by recommending specific modules or tasks. All therapists will complete training on the 3D programme and online therapy. Participants will receive guidance on how to use the 3D website before starting.
Also known as: 3D
This control arm provides psychoeducational content without therapist support or homework assignments, serving as an adjunct to standard care. This distinguishes it from the experimental arm, which includes therapist-guided interventions and active homework components.
Depression severity
Change in depressive symptoms, as measured by the 17-item Hamilton Depression Rating Scale (HDRS-17), validated in Spanish. Score range: 0 to 52; higher scores indicate more severe depression.
Time frame: Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline
Overall functioning
Change in overall functioning, measured using the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS 2.0, 36-item version), self-administered and validated in Spanish.The WHO-DAS 2.0 assesses functioning across six domains. Higher scores indicate greater disability. The Spanish version has demonstrated strong psychometric properties across psychiatric populations.
Time frame: Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline
Health-related quality of life
Change in health-related quality of life, assessed using the EQ-5D-5L, a self-reported questionnaire validated in Spanish. The EQ-5D-5L measures five dimensions. Each dimension is rated on a 5-point scale, and responses are combined into a single index score ranging from below 0 (very poor health) to 1 (perfect health). Additionally, a Visual Analogue Scale (VAS) is included, ranging from 0 (worst imaginable health) to 100 (best imaginable health).
Time frame: Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline.
Perceived Stress
Change in perceived stress, measured using the Perceived Stress Scale (PSS-10), a 10-item self-reported questionnaire validated in Spanish. Each item is rated on a 5-point scale from 0 (never) to 4 (very often). Total scores range from 0 to 40, with higher scores indicating greater levels of perceived stress.
Time frame: Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline.
Menstruation-related distress
Change in menstruation-related distress, measured using the Menstrual Distress Questionnaire (MEDI-Q), a 25-item self-reported tool assessing symptoms such as pain, discomfort, psychological changes, gastrointestinal issues, and physiological alterations. The MEDI-Q is a novel instrument and does not yet have a validated Spanish version; this study may contribute to its adaptation for Spanish-speaking populations.
Time frame: Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline.
Tryptophan metabolism biomarkers
Quantification of tryptophan and related metabolites (kynurenine, serotonin, 3-hydroxykynurenine, 5-hydroxyindoleacetic acid, kynurenic acid) and calculation of metabolic ratios (e.g., kynurenine/tryptophan ratio) using LC-MS/MS in biological samples (blood, saliva, urine, nails, hair). Higher or altered levels may be associated with treatment response.
Time frame: Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline.
Steroid hormone profile
Changes in hormone production and balance over time associated with intervention participation. Measurement of sex hormones (estradiol, testosterone, progesterone) and glucocorticoids (cortisol, 20α-DHE, 20β-DHE) and their metabolites using LC-MS/MS in biological samples (blood, saliva, urine, nails, hair). Hormonal alterations over time will be evaluated as potential markers of treatment effects.
Time frame: Baseline (T0): At enrolment/start of intervention. Post-intervention (T1): 3 months after baseline. Follow-up (T2): 6 months after baseline.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Started Mar 2026 (actual). Primary completion is estimated for Aug 2027, 17 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 17 months is below that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Mar 2026, on Oct 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.